In this white paper, we draw lessons from industries as diverse as food products and toy manufacturing to illustrate how pharmaceutical companies can effectively access innovation outside the traditional in-house R&D model. To read more, click the PDF link below. A version of this article was also published in IN VIVO here.
The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...